Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025) - Report - MDSpire
Advertisement
Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)
Trends and Current Insights on Immune-Related Adverse Events in Lung Cancer Patients
Overview
This bibliometric review analyzes the trends in research on immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in lung cancer from 2016 to 2025. It highlights the increasing publication volume, collaboration patterns, and evolving research hotspots in this critical area of oncology.
Background
Lung cancer remains the most prevalent and deadly cancer globally, necessitating effective treatment strategies. Immune checkpoint inhibitors have revolutionized lung cancer therapy, offering significant survival benefits; however, they are associated with potentially severe immune-related adverse events. Understanding the landscape of irAEs is crucial for optimizing patient management and improving outcomes.
Data Highlights
Year
Publications
2016-2019
Initial Phase
2020-2022
Rapid Increase Phase
2023-2025
Stable Development Phase
Key Findings
Annual publication volume on irAEs in lung cancer has shown a continuous upward trend from 2016 to 2025.
China leads globally with 626 publications, while the US has the highest betweenness centrality in collaboration networks.
Co-citation analysis revealed two major groups: landmark trials of ICIs and guidelines on irAE management.
Research hotspots have evolved from general safety in melanoma to lung cancer-specific high-risk irAEs and long-term prognosis analyses.
Clinical studies predominantly focus on combination immunotherapy, pulmonary toxicity, and biomarker-related analyses.
Clinical Implications
Healthcare professionals should be aware of the increasing incidence of irAEs in lung cancer patients treated with ICIs. Early recognition and management of these adverse events are essential to improve patient safety and treatment outcomes.
Conclusion
This bibliometric analysis underscores the growing body of research on irAEs in lung cancer, highlighting the need for continued investigation into high-risk populations and effective management strategies.
